A Safety Study of ARRY-403 in Patients With Type 2 Diabetes

Summary

This is a Phase 1 study, involving a 10-day dosing period, designed to test the safety of investigational study drug ARRY-403 (as monotherapy or in addition to stable metformin therapy) in patients with Type 2 diabetes. Approximately 128 patients from the US will be enrolled in this study.

Timeline

Start

2009-08

Primary completion

2010-08

Completion

2010-08

Drugs

Indications